INTRO

INTRO
KOR
CHN

GemVax & KAEL

GemVax & KAEL is dedicated to healthy lives and improved quality of human life

1989 ~ 2007

Initiation of R&D for telomerase-derived immunotherapeutic drug, GV1001™

1989 ~ 2007
DNA 이미지
DNA 이미지 DNA 이미지
1989

  • JAN

    GV1001 pioneering work in collaboration with
    Prof. Gaudernack (Norway Radium Hospital)

1997
  • Initiation of R&D for telomerase-derived
    immunotherapeutic drug

    JAN

1998

  • MAR

    Establishment of KAEL Environment Institute Co., Ltd.

1999
  • Corporate name change to KAEL Co., Ltd.

    APR
  • GV1001 substance patent filing

    JUN

2000

  • SEP

    GV1001 Pancreatic cancer clinical trial initiation
    (Ph I/II, CTN 1/2000)

2001
  • GV1001 Melanoma clinical trial initiation
    (Ph I/II, hTERT-1/01)

    AUG
  • GV1001 Non-Small cell lung cancer clinical trial initiation
    (Ph I/II, CTN 3/2000)

    SEP
  • Establishment of GemVax AS (Norway)

    OCT

2003

  • OCT

    GV1001 Pancreatic cancer clinical trial initiation
    (Ph I/II, CTN 7/2003)

  • NOV

    GV1001 Pancreatic cancer clinical trial initiation
    (Ph I/II, CTN 6/2003)
    GV1001 Melanoma clinical trial initiation (Ph II, PO3700)

2004
  • GV1001 Pancreatic cancer clinical trial initiation
    (Ph I/II, CTN 4/2003)

    JAN

2005

  • JUN

    Listed on KOSDAQ

2006
  • GV1001 Pancreatic cancer clinical trial initiation
    (Ph II, PrimoVax)

    JUN
  • GV1001 Orphan Drug designation (FDA&EMA)

    JUL
  • GV1001 Liver cancer clinical trial initiation
    (Ph II, HeptoVax)
    GV1001 Non-Small cell lung cancer clinical trial initiation
    (Ph II, CTN 8/2006)

    NOV

2007

  • MAR

    GV1001 Pancreatic cancer clinical trial initiation
    (Ph III, TeloVac)

  • JUN

    Establishment of VaxOnco Co., Ltd.

2008 ~ 2013

To grow as a biopharmaceutical company

2008 ~ 2013
DNA 이미지
2008

  • OCT

    Establishment of KAEL-GemVax Co., Ltd. Acquisition of GemVax AS by KAEL-GemVax Co., Ltd. from Pharmexa AS

2009
  • Acquisition of Epimmune Inc. (US based DNA vaccine development corporation) by VaxOnco Co., Ltd.

    APR
  • Acquisition of Ony-P technology by
    VaxOnco Co., Ltd. from OnyVax Ltd.

    JUL
  • Corporate name change from KAEl Co., Ltd to
    GemVax & KAEL Co., Ltd.

    DEC

2011

  • JUL

    Establishment of Shanghai GemVax & KAEL Co., Ltd. Merge of VaxOnco Co., Ltd. by KAEL-GemVax Co., Ltd.

2013
  • Acquisition of GemVax Technology Co., Ltd.

    MAR
  • GV1001 TeloVac trial result presented at 2013 ASCO

    JUN
  • 5aver, awarded the best of best prize of
    Red Dot design award

    JUL
  • GV1001 NDA submission for pancreatic cancer treatment (KR)

    SEP

2014 ~ 2015

Development of RIAVAX™inj.

2014 ~ 2015
DNA 이미지
DNA 이미지 DNA 이미지
2014

  • MAR

    GV1001 IND submission for prostate cancer clinical trial
    (Ph III, KR)

2014
  • GV1001 IND approval for prostate cancer clinical trial
    (Ph III, KR)
    Acquisition of Samsung Pharm Co., Ltd. TeloVac subgroup analysis presented at 2014 ASCO

    MAY

2014

  • SEP

    NDA approval of RIAVAX™inj. as an immunotherapeutic drug for pancreatic cancer treatment (KR) GV1001 IND submission of BPH clinical trial (Ph II, KR)

2014
  • Awarded the top prize of Korea New Drug Product Award (MFDS)

    OCT
  • Certification of KAEL-GemVax Co., Ltd. as an innovative pharmaceutical company (MOHW)

    NOV
  • GV1001 IND approval of BPH clinical trial (Ph II, KR) Merge of KAEL-GemVax Co., Ltd.

    DEC

2015

  • FEB

    GV1001 IND submission for pancreatic cancer clinical trial (Ph III, KR)

  • MAR

    GV1001 IND approval for pancreatic cancer clinical trial (Ph III, KR)

2015
  • License agreement execution with Samsung Pharm Co., Ltd. for RIAVAX™inj. marketing and manufacturing (KR)

    APR
  • Establishment of Hualian GemVax Co., Ltd.

    JUL

2015

  • SEP

    Certified as a corporation with venture business

  • NOV

    RIAVAX™inj. launch

  • DEC

    Acquisition of Kingsmen Co., Ltd.

2016 ~ 2017

Take a leap as a global biopharmaceutical company

2016 ~ 2017
DNA 이미지
2016

  • JUN

    Patient recruitment completion for GV1001 BPH clinical trial (Ph II, KR)

2016
  • GV1001 IND approval of Alzheimer’s disease clinical trial (Ph II, KR)

    DEC

2017

  • FEB

    MoU with Korea Drug Development Fund for treatment of Alzheimer’s disease with GV1001

  • MAR

    Execution of a drug product manufacturing contract with CDMO, Vetter for a global clinical trial of Alzheimer’s disease Execution of a CRO contract with PAREXEL for a global clinical trial of Alzheimer’s disease

  • MAY

    GV1001 BPH Clinical trial completion (Ph II, KR)

2017
  • GV1001 Alzheimer’s disease clinical trial initiation. (Ph II, KR)

    AUG
  • Results of Ph II GV1001 BPH clinical trial presented at Asia Pacific Prostate Society

    OCT
  • Won the Grand prize at the 9th SME IP management competition (KR)

    NOV

2018~Present

Take a leap as a global biopharmaceutical company

2018~Present
DNA 이미지
2018

  • MAR

    GV1001 Ph II BPH clinical trial results won the top publication award at the Korean Prostate Society GV1001 Ph II BPH clinical trial results presented at European Association Urology

  • APR

    GV1001 Ph II BPH clinical trial results published in the international journal, BJU International

2018
  • Patient recruitment completion for GV1001 Pancreatic cancer clinical trial (Ph III, KR)

    NOV

2019
  • Patient recruitment completion for GV1001 Alzheimer’s disease clinical trial (Ph II, KR)

    MAR

  • APR

    GV1001 IND approval of BPH clinical trial (Ph III, KR)

  • MAY

    GV1001 FDA IND approval of Alzheimer’s disease clinical trial (Ph II, US)